ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The award was presented to ClearFlow for its development of the PleuraFlow Active Clearance Technology (ACT) System, which has been clinically shown to reduce the occurrence of complications after cardiac surgery, according to the company.

Having a non-O blood group is associated with a higher risk of heart attack, according to research presented at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure, April 29-May 2 in Paris, France.

Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than evaluating commonly-used risk factors in determining whether a person will have a heart attack, stroke or major cardiac event. Researchers believe the data, published in the American Journal of Cardiology (AJC), could revolutionize how doctors identify patients — not only higher-risk patients who need aggressive treatment, but also lower-risk patients who could avoid expensive and invasive procedures.

Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new method for producing positron emission tomography (PET) radiotracers. The discovery utilizes the transition metal rhenium to promote fluorine-18 radiolabelling under aqueous, low temperature conditions.